Related Experiment Video
Updated: Jun 15, 2026
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Itk inhibitors: a patent review
1Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA. ho-yin.lo@boehringer-ingelheim.com
Expert Opinion on Therapeutic Patents
|March 12, 2010
Summary
Selective inhibitors of IL-2 inducible T-cell kinase (Itk) show promise for treating inflammatory diseases. While many compounds demonstrate efficacy in animal models, none have reached clinical trials, highlighting the need for further development.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- IL-2 inducible T-cell kinase (Itk) is a Tec family tyrosine kinase crucial for T cell signaling and pro-inflammatory cytokine production.
- Itk inhibition is a therapeutic strategy for inflammatory conditions like psoriasis and allergic asthma.
- Extensive structural data has facilitated the development of novel selective Itk inhibitors.
Purpose of the Study:
- To summarize distinct structural classes of specific Itk inhibitors.
- To discuss the in vitro and in vivo properties of these inhibitors.
- To review recent advancements in Itk inhibitor discovery.
Main Methods:
- Literature review of patents and scientific publications.
- Analysis of chemical structures and properties of Itk inhibitors.
- Evaluation of in vitro and in vivo data from preclinical studies.
Main Results:
- A review of 21 patents encompassing 16 distinct chemical structure classes of Itk inhibitors.
- Discussion of the in vivo efficacy of selected Itk inhibitors in animal models.
- Identification of key structural features contributing to Itk inhibition.
Conclusions:
- Several Itk inhibitors exhibit efficacy in preclinical animal models, suggesting therapeutic potential.
- No Itk inhibitor has yet entered clinical trials.
- Future prospects depend on compound quality and target validation in human patients.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...